Cargando…

Consolidation treatments after chemoradiotherapy in patients with locally advanced inoperable non-small cell lung cancer: a systematic review and network meta-analysis protocol

INTRODUCTION: Concurrent chemoradiotherapy (CCRT) is the standard of care for inoperable locally advanced non-small cell lung cancer. To further improve prognosis, the use of consolidation treatments after CCRT has been explored extensively. Although durvalumab is the only consolidation treatment re...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Ye, Feng, Haiming, Tian, Jinhui, Li, Bin, Wang, Cheng, Ge, Long, Wang, Jian kai, Yang, Kehu, Yu, Qin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006802/
https://www.ncbi.nlm.nih.gov/pubmed/35414564
http://dx.doi.org/10.1136/bmjopen-2022-060900
_version_ 1784686737282301952
author Zhao, Ye
Feng, Haiming
Tian, Jinhui
Li, Bin
Wang, Cheng
Ge, Long
Wang, Jian kai
Yang, Kehu
Yu, Qin
author_facet Zhao, Ye
Feng, Haiming
Tian, Jinhui
Li, Bin
Wang, Cheng
Ge, Long
Wang, Jian kai
Yang, Kehu
Yu, Qin
author_sort Zhao, Ye
collection PubMed
description INTRODUCTION: Concurrent chemoradiotherapy (CCRT) is the standard of care for inoperable locally advanced non-small cell lung cancer. To further improve prognosis, the use of consolidation treatments after CCRT has been explored extensively. Although durvalumab is the only consolidation treatment recommended by national clinical practice guidelines, there have been many studies exploring the effectiveness of other agents. However, until now, no studies have compared all agents systematically, and no studies have provided evidence for the optimal combination of different CCRTs and consolidation treatments regimens. This systematic review will evaluate the comparative clinical efficacy of consolidation therapies after CCRT as well as various combinations of CCRTs and consolidation therapies. METHODS AND ANALYSIS: PubMed, the Cochrane Controlled Register of Trials (CENTRAL), EMBASE and ClinicalTrials.gov will be searched for relevant information. The estimated end date for the search will be 3 February 2022. Each stage of the review, including the study section, data extraction and risk of bias and quality of evidence assessments, will be performed in duplicate. We will include randomised controlled trials that included participants who received CCRT and consolidation treatment in at least one treatment arm. The primary endpoints will be overall survival and progression-free survival. Tumour response, health-related quality of life, disease-free survival and treatment-related toxicity will be presented as secondary outcomes. Both traditional meta-analysis and network meta-analysis (NMA) with the Bayesian approach will be conducted. Subgroup analyses and meta-regression will be completed to investigate heterogeneity, and sensitivity analyses will be conducted to assess the robustness of the findings. ETHICS AND DISSEMINATION: Ethical approval and patient consent are not required as this study is a meta-analysis based on published studies. The results of this study will be submitted to a peer-reviewed journal for publication. In case of any changes in the protocol, protocol amendments will be updated in PROSPERO and explanations of these modifications will be described in the final report of this review. The results of this systematic review and NMA will be published in a peer-reviewed journal. PROSPERO REGISTRATION NUMBER: CRD42021239433.
format Online
Article
Text
id pubmed-9006802
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-90068022022-05-02 Consolidation treatments after chemoradiotherapy in patients with locally advanced inoperable non-small cell lung cancer: a systematic review and network meta-analysis protocol Zhao, Ye Feng, Haiming Tian, Jinhui Li, Bin Wang, Cheng Ge, Long Wang, Jian kai Yang, Kehu Yu, Qin BMJ Open Oncology INTRODUCTION: Concurrent chemoradiotherapy (CCRT) is the standard of care for inoperable locally advanced non-small cell lung cancer. To further improve prognosis, the use of consolidation treatments after CCRT has been explored extensively. Although durvalumab is the only consolidation treatment recommended by national clinical practice guidelines, there have been many studies exploring the effectiveness of other agents. However, until now, no studies have compared all agents systematically, and no studies have provided evidence for the optimal combination of different CCRTs and consolidation treatments regimens. This systematic review will evaluate the comparative clinical efficacy of consolidation therapies after CCRT as well as various combinations of CCRTs and consolidation therapies. METHODS AND ANALYSIS: PubMed, the Cochrane Controlled Register of Trials (CENTRAL), EMBASE and ClinicalTrials.gov will be searched for relevant information. The estimated end date for the search will be 3 February 2022. Each stage of the review, including the study section, data extraction and risk of bias and quality of evidence assessments, will be performed in duplicate. We will include randomised controlled trials that included participants who received CCRT and consolidation treatment in at least one treatment arm. The primary endpoints will be overall survival and progression-free survival. Tumour response, health-related quality of life, disease-free survival and treatment-related toxicity will be presented as secondary outcomes. Both traditional meta-analysis and network meta-analysis (NMA) with the Bayesian approach will be conducted. Subgroup analyses and meta-regression will be completed to investigate heterogeneity, and sensitivity analyses will be conducted to assess the robustness of the findings. ETHICS AND DISSEMINATION: Ethical approval and patient consent are not required as this study is a meta-analysis based on published studies. The results of this study will be submitted to a peer-reviewed journal for publication. In case of any changes in the protocol, protocol amendments will be updated in PROSPERO and explanations of these modifications will be described in the final report of this review. The results of this systematic review and NMA will be published in a peer-reviewed journal. PROSPERO REGISTRATION NUMBER: CRD42021239433. BMJ Publishing Group 2022-04-11 /pmc/articles/PMC9006802/ /pubmed/35414564 http://dx.doi.org/10.1136/bmjopen-2022-060900 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Oncology
Zhao, Ye
Feng, Haiming
Tian, Jinhui
Li, Bin
Wang, Cheng
Ge, Long
Wang, Jian kai
Yang, Kehu
Yu, Qin
Consolidation treatments after chemoradiotherapy in patients with locally advanced inoperable non-small cell lung cancer: a systematic review and network meta-analysis protocol
title Consolidation treatments after chemoradiotherapy in patients with locally advanced inoperable non-small cell lung cancer: a systematic review and network meta-analysis protocol
title_full Consolidation treatments after chemoradiotherapy in patients with locally advanced inoperable non-small cell lung cancer: a systematic review and network meta-analysis protocol
title_fullStr Consolidation treatments after chemoradiotherapy in patients with locally advanced inoperable non-small cell lung cancer: a systematic review and network meta-analysis protocol
title_full_unstemmed Consolidation treatments after chemoradiotherapy in patients with locally advanced inoperable non-small cell lung cancer: a systematic review and network meta-analysis protocol
title_short Consolidation treatments after chemoradiotherapy in patients with locally advanced inoperable non-small cell lung cancer: a systematic review and network meta-analysis protocol
title_sort consolidation treatments after chemoradiotherapy in patients with locally advanced inoperable non-small cell lung cancer: a systematic review and network meta-analysis protocol
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006802/
https://www.ncbi.nlm.nih.gov/pubmed/35414564
http://dx.doi.org/10.1136/bmjopen-2022-060900
work_keys_str_mv AT zhaoye consolidationtreatmentsafterchemoradiotherapyinpatientswithlocallyadvancedinoperablenonsmallcelllungcancerasystematicreviewandnetworkmetaanalysisprotocol
AT fenghaiming consolidationtreatmentsafterchemoradiotherapyinpatientswithlocallyadvancedinoperablenonsmallcelllungcancerasystematicreviewandnetworkmetaanalysisprotocol
AT tianjinhui consolidationtreatmentsafterchemoradiotherapyinpatientswithlocallyadvancedinoperablenonsmallcelllungcancerasystematicreviewandnetworkmetaanalysisprotocol
AT libin consolidationtreatmentsafterchemoradiotherapyinpatientswithlocallyadvancedinoperablenonsmallcelllungcancerasystematicreviewandnetworkmetaanalysisprotocol
AT wangcheng consolidationtreatmentsafterchemoradiotherapyinpatientswithlocallyadvancedinoperablenonsmallcelllungcancerasystematicreviewandnetworkmetaanalysisprotocol
AT gelong consolidationtreatmentsafterchemoradiotherapyinpatientswithlocallyadvancedinoperablenonsmallcelllungcancerasystematicreviewandnetworkmetaanalysisprotocol
AT wangjiankai consolidationtreatmentsafterchemoradiotherapyinpatientswithlocallyadvancedinoperablenonsmallcelllungcancerasystematicreviewandnetworkmetaanalysisprotocol
AT yangkehu consolidationtreatmentsafterchemoradiotherapyinpatientswithlocallyadvancedinoperablenonsmallcelllungcancerasystematicreviewandnetworkmetaanalysisprotocol
AT yuqin consolidationtreatmentsafterchemoradiotherapyinpatientswithlocallyadvancedinoperablenonsmallcelllungcancerasystematicreviewandnetworkmetaanalysisprotocol